Stiris Research Inc. Awarded a Phase 2 Nephropathy Study

London, ON — 17 November 2020 —

Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announces it has been awarded a Phase II Proof of Concept Study in various Nephropathies.

“Stiris’ is excited for the opportunity to work in a new area of focus for us. Diseases and malfunctions of the kidneys is a therapeutic area that our team has a keen interest in as well as working in the area of autoantibodies. We are always grateful to be working with biotechnology companies whose focus is on treatments for Rare Diseases and/or Genetic Conditions,” Amanda Carrera, Vice President.

Renal Disease is a term given for a number of diseases that can affect the functionality of a patient’s kidneys. The impact of renal disease can vary considerably from acute conditions to rare and genetic diseases. Treatments options for the various disease differ and many do not have specific therapies.

About Stiris Research

Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies, with a focus on Oncology, CNS and Neurology. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.

For more information, please contact:

Marketing – Stiris Research Inc.